431 related articles for article (PubMed ID: 36213111)
21. Pan-cancer analysis predicts CANT1 as a potential prognostic, immunologic biomarker.
Yang W; Liu Z; Liu T
Cell Signal; 2024 May; 117():111107. PubMed ID: 38369265
[TBL] [Abstract][Full Text] [Related]
22. Pan-Cancer Analysis Based on
Zhang Y; Wang S; Han S; Feng Y
Front Oncol; 2022; 12():844794. PubMed ID: 35359375
[TBL] [Abstract][Full Text] [Related]
23. Clinical and immunological characteristics of TGM3 in pan-cancer: A potential prognostic biomarker.
Zhang W; Wu C; Zhou K; Cao Y; Zhou W; Zhang X; Deng D
Front Genet; 2022; 13():993438. PubMed ID: 36685895
[No Abstract] [Full Text] [Related]
24.
Wu G; Chen M; Ren H; Sha X; He M; Ren K; Qi J; Lin F
Front Cell Dev Biol; 2022; 10():930933. PubMed ID: 35874816
[No Abstract] [Full Text] [Related]
25. RelB is a potential molecular biomarker for immunotherapy in human pan-cancer.
Wu J; Yu X; Zhu H; Chen P; Liu T; Yin R; Qiang Y; Xu L
Front Mol Biosci; 2023; 10():1178446. PubMed ID: 37388242
[No Abstract] [Full Text] [Related]
26. Siglec-9, a Putative Immune Checkpoint Marker for Cancer Progression Across Multiple Cancer Types.
Wu Y; Huang W; Xie Y; Wang C; Luo N; Chen Y; Wang L; Cheng Z; Gao Z; Liu S
Front Mol Biosci; 2022; 9():743515. PubMed ID: 35372497
[TBL] [Abstract][Full Text] [Related]
27. CXCL11 Correlates with Immune Infiltration and Impacts Patient Immunotherapy Efficacy: A Pan-Cancer Analysis.
Li Y; Han S; Wu B; Zhong C; Shi Y; Lv C; Fu L; Zhang Y; Lang Q; Liang Z; Yu Y; Tian Y
Front Immunol; 2022; 13():951247. PubMed ID: 35935945
[TBL] [Abstract][Full Text] [Related]
28. GRAMD1A Is a Biomarker of Kidney Renal Clear Cell Carcinoma and Is Associated with Immune Infiltration in the Tumour Microenvironment.
Liu Y; Fu S; Zhang Z; Wang S; Cheng X; Li Z; Ding Y; Sun T; Ma M
Dis Markers; 2022; 2022():5939021. PubMed ID: 35860689
[TBL] [Abstract][Full Text] [Related]
29. Inflammatory response signature score model for predicting immunotherapy response and pan-cancer prognosis.
Chen S; Huang M; Zhang L; Huang Q; Wang Y; Liang Y
Comput Struct Biotechnol J; 2024 Dec; 23():369-383. PubMed ID: 38226313
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive pan-cancer analysis of role of GPRASP1, associated with clinical outcomes, immune microenvironment, and immunotherapeutic efficiency in pancreatic cancer.
Du J; Chen Y; Liu G; Zeng Q; Zhou N; Du D
Pathol Res Pract; 2023 Mar; 243():154374. PubMed ID: 36801507
[TBL] [Abstract][Full Text] [Related]
31. A Comprehensive Pan-Cancer Analysis of 33 Human Cancers Reveals the Immunotherapeutic Value of Aryl Hydrocarbon Receptor.
Mo Z; Li P; Cao Z; Zhang S
Front Immunol; 2021; 12():564948. PubMed ID: 34290693
[TBL] [Abstract][Full Text] [Related]
32. Pan-Cancer Analysis Identified CD93 as a Valuable Biomarker for Predicting Patient Prognosis and Immunotherapy Response.
Tong W; Wang G; Zhu L; Bai Y; Liu Z; Yang L; Wu H; Cui T; Zhang Y
Front Mol Biosci; 2021; 8():793445. PubMed ID: 35265666
[No Abstract] [Full Text] [Related]
33. Pan-cancer analysis reveals RIPK2 predicts prognosis and promotes immune therapy resistance via triggering cytotoxic T lymphocytes dysfunction.
Song J; Yang R; Wei R; Du Y; He P; Liu X
Mol Med; 2022 May; 28(1):47. PubMed ID: 35508972
[TBL] [Abstract][Full Text] [Related]
34. Pan-cancer integrated bioinformatics analysis reveals cuproptosis related gene FDX1 is a potential prognostic and immunotherapeutic biomarker for lower-grade gliomas.
Huang W; Wu Y; Zhu J; Luo N; Wang C; Liu S; Cheng Z
Front Mol Biosci; 2023; 10():963639. PubMed ID: 36825202
[TBL] [Abstract][Full Text] [Related]
35. Pan-Cancer Molecular Characterization of m
Zhu J; Xiao J; Wang M; Hu D
Front Oncol; 2020; 10():618374. PubMed ID: 33585244
[TBL] [Abstract][Full Text] [Related]
36. A pan-cancer analysis to determine the prognostic analysis and immune infiltration of HSPA5.
Zhu RK; Zhang W; Zhang YX; Hui Z; Wang XW
Curr Cancer Drug Targets; 2023 May; ():. PubMed ID: 37157205
[TBL] [Abstract][Full Text] [Related]
37. Comprehensive pan-cancer analysis of 33 human cancers reveals immunotherapeutic value of focal adhesion tyrosine kinase.
Shi Y; Ju M; Zhang Y; Liang L; Sun X; Di X
Medicine (Baltimore); 2024 Mar; 103(12):e37362. PubMed ID: 38518034
[TBL] [Abstract][Full Text] [Related]
38. Pan-Cancer Integrated Analysis of HSF2 Expression, Prognostic Value and Potential Implications for Cancer Immunity.
Chen F; Fan Y; Liu X; Zhang J; Shang Y; Zhang B; Liu B; Hou J; Cao P; Tan K
Front Mol Biosci; 2021; 8():789703. PubMed ID: 35087869
[TBL] [Abstract][Full Text] [Related]
39. LRP1B mutation is associated with tumor immune microenvironment and progression-free survival in lung adenocarcinoma treated with immune checkpoint inhibitors.
He Z; Feng W; Wang Y; Shi L; Gong Y; Shi Y; Shen S; Huang H
Transl Lung Cancer Res; 2023 Mar; 12(3):510-529. PubMed ID: 37057124
[TBL] [Abstract][Full Text] [Related]
40. Pan-cancer analysis identifies migrasome-related genes as a potential immunotherapeutic target: A bulk omics research and single cell sequencing validation.
Qin Y; Yang J; Liang C; Liu J; Deng Z; Yan B; Fu Y; Luo Y; Li X; Wei X; Li W
Front Immunol; 2022; 13():994828. PubMed ID: 36405728
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]